<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780464</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1976-STBSG</org_study_id>
    <secondary_id>2021-000125-27</secondary_id>
    <nct_id>NCT04780464</nct_id>
  </id_info>
  <brief_title>A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma</brief_title>
  <acronym>Tolerance</acronym>
  <official_title>a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Every Three Weeks or Doxorubicin Weekly or Cyclophosphamide Plus Prednisolone Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, open label, randomized phase 3 selection study (1:2:2 randomization).&#xD;
&#xD;
      After confirmation of the eligibility criteria, 185 patients will be randomized 1:2:2 to&#xD;
      either the control arm (doxorubicin 60-75 mg/m² IV every 3 weeks) or experimental arm 1&#xD;
      (doxorubicin 12 mg/m2 IV every week) or experimental arm 2 (cyclophosphamide 100 mg orally BD&#xD;
      plus prednisolone 10-20 mg orally on day 1 to day 7 of each 14 day cycle).&#xD;
&#xD;
      HRQoL assessment will be performed every 3 weeks during the first 12 weeks and every 12 weeks&#xD;
      thereafter until month 12 after start of treatment.&#xD;
&#xD;
      Disease evaluation will be performed every 12 weeks until progression. The primary endpoint&#xD;
      of the study is difference among the study arms in physical and role functioning at 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>4 years after first patient in</time_frame>
    <description>Difference in physical and role functioning at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response</measure>
    <time_frame>5.5 years after first patient in</time_frame>
    <description>tumor response according to RECIST criteria (version 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>5.5 years after first patient in</time_frame>
    <description>Progression-free-survival from the date of randomization to the date of first progression or death, whatever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5.5 years after first patient in</time_frame>
    <description>Overall survival from the date of randomization to the date of death, whatever the cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Advanced Soft-tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Standard doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronomic doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronomic oral cyclophosphamide + prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD</description>
    <arm_group_label>Standard doxorubicin</arm_group_label>
    <other_name>Adriamycin;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD</description>
    <arm_group_label>Metronomic doxorubicin</arm_group_label>
    <other_name>Adriamycin;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide Oral Product</intervention_name>
    <description>100 mg BD on day 1 to day 7 of each 14 day cycle until PD</description>
    <arm_group_label>Metronomic oral cyclophosphamide + prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>10-20 mg on day 1 to day 7 of each 14 day cycle until PD</description>
    <arm_group_label>Metronomic oral cyclophosphamide + prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven advanced unresectable or metastatic soft tissue sarcoma&#xD;
&#xD;
          -  Representative formalin fixed, paraffin embedded tumor blocks or a minimum of 10&#xD;
             unstained tissue slides, either from the primary tumor or a metastatic lesion, must be&#xD;
             available for histological central review. Histological central review is not required&#xD;
             before treatment start but it is mandatory to send at least 10 unstained tumor slides&#xD;
             (blocks optional) at time of study entry. Local histopathological diagnosis will be&#xD;
             accepted for entry into this trial.&#xD;
&#xD;
          -  Age ≥ 65 years of age (patients between 65 and 69 years old are eligible if G8 score ≤&#xD;
             14; patients ≥ 70 years old are eligible independent of G8 score)&#xD;
&#xD;
          -  WHO performance status 0 - 2&#xD;
&#xD;
          -  Life expectancy based on other significant morbidity of ≥ 6 months&#xD;
&#xD;
          -  Presence of measurable disease (according to RECIST 1.1), as confirmed by imaging&#xD;
             within the 28 days prior to randomization. CT with IV contrast is the preferred&#xD;
             imaging modality. In case of any contra-indications (medical or regulatory), it is&#xD;
             allowed to perform a non-contrast CT + MRI.&#xD;
&#xD;
          -  Progressive disease at entry based on RECIST 1.1&#xD;
&#xD;
          -  Patients amenable to receive doxorubicin according to investigator's assessment&#xD;
&#xD;
          -  Adequate haematological and organ function assessed prior to randomization:&#xD;
&#xD;
          -  Haematological function:&#xD;
&#xD;
               -  haemoglobin ≥ 9.0 g/dL or 5.6 mmol/L&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Coagulation: partial thromboplastin time (PTT) ≤ 1.0 times upper limit of normal&#xD;
                  (1.0 x ULN) of institutional limits and prothrombin time (PT) ≤ 1.0 x ULN of&#xD;
                  institutional limits&#xD;
&#xD;
          -  Renal function: estimated glomerular filtration rate (eGFR) &gt; 50 ml/min/m2 (calculated&#xD;
             by the MDRD formula in appendix E); no proteinuria ≥ grade 2 (CTCAE version 5.0);&#xD;
&#xD;
          -  Hepatic function: bilirubin ≤ 1.0 x ULN of institutional limits, alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase (AST) ≤1.5 x ULN.&#xD;
&#xD;
        If isolated elevated bilirubin &lt;2 x ULN and Gilberts syndrome suspected, suggest repeating&#xD;
        bloods after food. If bilirubin improves to meet the criteria above this is acceptable.&#xD;
        More severe persistent hepatic impairment of whatever cause would exclude the patient from&#xD;
        treatment till resolved.&#xD;
&#xD;
          -  Cardiac function: clinically normal function based on the institutional lower limit of&#xD;
             normal for left ventricular ejection fraction (LVEF) as assessed either by multi-gated&#xD;
             acquisition scan (MUGA) or cardiac ultrasound and 12 lead electrocardiogram (ECG)&#xD;
             without clinically relevant abnormalities. Measurement should include investigator&#xD;
             assessment of a potential participant's risk for heart failure with a validated&#xD;
             clinical classification system, i.e. the New York Heart Association Functional&#xD;
             Classification. Only patients with NYHA class 1 and 2 according to appendix D are&#xD;
             eligible.&#xD;
&#xD;
          -  Completion of EORTC QLQ-C30 and EORTC QLQ-ELD14 at baseline.&#xD;
&#xD;
          -  Assessment of G8 geriatric screening tool&#xD;
&#xD;
          -  Assessment of Katz Index of Independence in Activities of Daily Living (ADL)&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agreement to refrain from donating sperm, as defined&#xD;
             below:&#xD;
&#xD;
          -  With female partners of childbearing potential, men must remain abstinent or use a&#xD;
             condom during the treatment period and for a period of 6 months after the last dose of&#xD;
             doxorubicin-based chemotherapy and for a period of 12 months after the last dose of&#xD;
             cyclophosphamide-based chemotherapy. Men must refrain from donating sperm during this&#xD;
             same period. Contraception should be considered for the female partners of&#xD;
             childbearing potential as well.&#xD;
&#xD;
          -  With pregnant female partners, men must remain abstinent or use a condom during the&#xD;
             treatment period and for a period of 6 months after the last dose of doxorubicin-based&#xD;
             chemotherapy and for a period of 12 months after the last dose of&#xD;
             cyclophosphamide-based chemotherapy to avoid exposing the embryo.&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to ICH/GCP, and national/local regulations including commitment to&#xD;
             completing questionnaires during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or known brain metastasis&#xD;
&#xD;
          -  Any prior treatment with anthracyclines&#xD;
&#xD;
          -  Any prior systemic treatment for metastatic STS&#xD;
&#xD;
          -  Inability to swallow and/ or retain oral tablets&#xD;
&#xD;
          -  Rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  Hypersensitivity to doxorubicin, cyclophosphamide, prednisolone or to any of their&#xD;
             metabolites or to any of their excipients&#xD;
&#xD;
          -  Uncontrolled severe illness, including but not limited to:&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Angina pectoris&#xD;
&#xD;
          -  Acute inflammatory heart disease&#xD;
&#xD;
          -  Myocardial infarction within 1 year before randomization&#xD;
&#xD;
          -  Arterial hypertension defined as blood pressure ≥ 150/100 mm Hg despite optimal&#xD;
             medical therapy&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Increased haemorragic tendency&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Bone marrow aplasia&#xD;
&#xD;
          -  Psychosis&#xD;
&#xD;
          -  Active or uncontrolled infections among which those requiring systemic antibiotics or&#xD;
             antimicrobial therapy.&#xD;
&#xD;
          -  Inflammation of the urinary bladder (interstitial cystitis) and/or obstructions of the&#xD;
             urine flow.&#xD;
&#xD;
          -  Vaccination with live vaccines within 30 days prior to study entry&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment has&#xD;
             the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are not eligible for this trial.&#xD;
&#xD;
          -  Known contraindication to imaging tracer or contrast medium and contraindication to&#xD;
             MRI&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and its active requirements (including&#xD;
             completion of questionnaires) and follow-up schedule; those conditions should be&#xD;
             discussed with the patient before randomization in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winette van der Graaf</last_name>
    <role>Study Chair</role>
    <affiliation>Nationaal Kanker Instituut, Amsterdam, NL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>eortc@eortc.org</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

